US92915B1061

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimers DiseaseVoyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimers Disease

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimers Disease

November 20, 2024 07:00 ET | Source: Voyager Therapeutics, Inc. - Candidate VY1706 demonstrates significant reductions of tau at low…

5 months ago